The FDAs enforcement action against Purolea Cosmetics Lab offers an early look at how the agency expects AI-generated work to fit within existing quality systems, with experts saying human oversight and quality controls remain essential.
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers